Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
<b>:</b><b> </b>Immunotherapy based on anti PD-1/PD-L1 inhibitors has proven to be more effective than sunitinib in the first-line setting of advanced renal cell carcinoma (RCC). RCC patients with sarcomatoid histology (sRCC) have a poor prognosis and limited therapeutic opti...
Main Authors: | Carlo Buonerba, Pasquale Dolce, Simona Iaccarino, Luca Scafuri, Antonio Verde, Ferdinando Costabile, Martina Pagliuca, Rocco Morra, Vittorio Riccio, Dario Ribera, Pietro De Placido, Valeria Romeo, Felice Crocetto, Nicola Longo, Ciro Imbimbo, Sabino De Placido, Giuseppe Di Lorenzo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/2/408 |
Similar Items
-
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
by: Kazuya Tsubouchi, et al.
Published: (2020-04-01) -
Impressive response to nivolumab of non‐small‐cell lung cancer containing sarcomatoid components
by: Takahiro Ota, et al.
Published: (2019-11-01) -
Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
by: Kazumi Nishino, et al.
Published: (2020-04-01) -
Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
by: Renate Pichler, et al.
Published: (2019-03-01) -
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
by: Baldovini C, et al.
Published: (2019-12-01)